Drug Profile
Research programme: inflammatory and autoimmune disease therapeutics - Johnson & Johnson
Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Johnson & Johnson; Sunesis Pharmaceuticals
- Developer Johnson & Johnson
- Class Small molecules
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 29 Jun 2009 Discontinued - Preclinical for Psoriasis in USA (PO)
- 29 Jun 2009 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)